Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision

L. van der Heijden; M.A.J. van de Sande; I. C.M. van der Geest; H. W.B. Schreuder; Barend J. Van Royen; P.C. Jutte; Jos A M Bramer; F. C. Öner; A.P. van Noort-Suijdendorp; H.M. Kroon; P D S Sander Dijkstra

doi:10.1007/s00586-014-3263-5

Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision

L. van der Heijden
, M.A.J. van de Sande
, I. C.M. van der Geest
, H. W.B. Schreuder
, Barend J. Van Royen
, P.C. Jutte
, Jos A M Bramer
, F. C. Öner
, A.P. van Noort-Suijdendorp
, H.M. Kroon
, P D S Sander Dijkstra

Regenerative Medicine and Stem Cells

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

PURPOSE: Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT).

METHODS: We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U.

RESULTS: Recurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024).

CONCLUSION: Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function.

Original language	English
Pages (from-to)	1949-1962
Number of pages	14
Journal	European Spine Journal
Volume	23
Issue number	9
DOIs	https://doi.org/10.1007/s00586-014-3263-5
Publication status	Published - 1 Sept 2014

Access to Document

10.1007/s00586-014-3263-5

http://www.ncbi.nlm.nih.gov/pubmed/24614982

Cite this

van der Heijden, L., van de Sande, M. A. J., van der Geest, I. C. M., Schreuder, H. W. B., Van Royen, B. J., Jutte, P. C., Bramer, J. A. M., Öner, F. C., van Noort-Suijdendorp, A. P., Kroon, H. M., & Dijkstra, P. D. S. S. (2014). Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision. European Spine Journal, 23(9), 1949-1962. https://doi.org/10.1007/s00586-014-3263-5

@article{744c295f453b41bf9248e33dce08c3a9,

title = "Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision",

abstract = "PURPOSE: Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT).METHODS: We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U.RESULTS: Recurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 \% CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024).CONCLUSION: Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function.",

author = "\{van der Heijden\}, L. and \{van de Sande\}, M.A.J. and \{van der Geest\}, \{I. C.M.\} and Schreuder, \{H. W.B.\} and \{Van Royen\}, \{Barend J.\} and P.C. Jutte and Bramer, \{Jos A M\} and {\"O}ner, \{F. C.\} and \{van Noort-Suijdendorp\}, A.P. and H.M. Kroon and Dijkstra, \{P D S Sander\}",

year = "2014",

month = sep,

day = "1",

doi = "10.1007/s00586-014-3263-5",

language = "English",

volume = "23",

pages = "1949--1962",

journal = "European Spine Journal",

issn = "0940-6719",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "9",

}

van der Heijden, L, van de Sande, MAJ, van der Geest, ICM, Schreuder, HWB, Van Royen, BJ, Jutte, PC, Bramer, JAM, Öner, FC, van Noort-Suijdendorp, AP, Kroon, HM & Dijkstra, PDSS 2014, 'Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision', European Spine Journal, vol. 23, no. 9, pp. 1949-1962. https://doi.org/10.1007/s00586-014-3263-5

TY - JOUR

T1 - Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision

AU - van der Heijden, L.

AU - van de Sande, M.A.J.

AU - van der Geest, I. C.M.

AU - Schreuder, H. W.B.

AU - Van Royen, Barend J.

AU - Jutte, P.C.

AU - Bramer, Jos A M

AU - Öner, F. C.

AU - van Noort-Suijdendorp, A.P.

AU - Kroon, H.M.

AU - Dijkstra, P D S Sander

PY - 2014/9/1

Y1 - 2014/9/1

N2 - PURPOSE: Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT).METHODS: We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U.RESULTS: Recurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024).CONCLUSION: Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function.

AB - PURPOSE: Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT).METHODS: We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U.RESULTS: Recurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024).CONCLUSION: Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function.

UR - https://www.scopus.com/pages/publications/85027922872

U2 - 10.1007/s00586-014-3263-5

DO - 10.1007/s00586-014-3263-5

M3 - Article

C2 - 24614982

SN - 0940-6719

VL - 23

SP - 1949

EP - 1962

JO - European Spine Journal

JF - European Spine Journal

IS - 9

ER -

Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision

Abstract

Access to Document

Other files and links

Fingerprint

Cite this